Abstract
Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have